|
Post by boytroy88 on May 2, 2018 8:10:25 GMT -5
|
|
|
Post by kbrion77 on May 2, 2018 8:32:32 GMT -5
Numbers will be brutal.
|
|
|
Post by slugworth008 on May 2, 2018 9:19:50 GMT -5
Agreed. Now who was it MNKD hired to find partnership opps? So many swing and misses - I can't keep count.
|
|
|
Post by bundy on May 2, 2018 9:27:50 GMT -5
At least It’s on middle of the week better than end of week. Due for some positive company development news.
|
|
|
Post by dreamboatcruise on May 3, 2018 13:44:20 GMT -5
At least It’s on middle of the week better than end of week. Due for some positive company development news. Long past that due date.
|
|
|
Post by cjc04 on May 8, 2018 10:18:38 GMT -5
Am I missing something?
If we averaged $600k / week in sales for the year, isn’t that well within the 2018 guidance? Not that I’m happy with $31.2 mil in sales, but I don’t understand the concern that they’ll lower guidance.
|
|
|
Post by dreamboatcruise on May 8, 2018 10:34:09 GMT -5
Am I missing something? If we averaged $600k / week in sales for the year, isn’t that well within the 2018 guidance? Not that I’m happy with $31.2 mil in sales, but I don’t understand the concern that they’ll lower guidance. Perhaps you're missing that retail sales reported by Symphony include money that goes to pharmacy and middlemen so that the revenue then actually received by Mannkind is much lower. If you're merely observing that $600k/wk in revenue would hit guidance, that may well be correct, but we've not come anywhere near that in recognizable revenue to Mannkind at this point. Guidance will be the single most important thing in my opinion, with a good outcome being the reiteration of their prior guidance (fingers crossed).
|
|
|
Post by matt on May 8, 2018 14:14:45 GMT -5
Am I missing something? If we averaged $600k / week in sales for the year, isn’t that well within the 2018 guidance? Not that I’m happy with $31.2 mil in sales, but I don’t understand the concern that they’ll lower guidance. dreamboatcruise explained it pretty well. For reference, the difference between retail sales reported by Symphony and net sales reported by Mannkind has been running about 50%. Also you should be aware of "good news, bad news" announcements such as the agreement for CVS/Caremark to list Afrezza on some of their tier 3/4 formularies. The good news is that more patients will have at least some insurance coverage for their medication and that could help future retail sales, but the bad news is that CVS/Caremark didn't agree to that deal without the promise of a rebate which will further reduce the gross retail to net reported sales difference.
|
|
|
Post by peppy on May 8, 2018 14:23:35 GMT -5
Am I missing something? If we averaged $600k / week in sales for the year, isn’t that well within the 2018 guidance? Not that I’m happy with $31.2 mil in sales, but I don’t understand the concern that they’ll lower guidance. dreamboatcruise explained it pretty well. For reference, the difference between retail sales reported by Symphony and net sales reported by Mannkind has been running about 50%. Also you should be aware of "good news, bad news" announcements such as the agreement for CVS/Caremark to list Afrezza on some of their tier 3/4 formularies. The good news is that more patients will have at least some insurance coverage for their medication and that could help future retail sales, but the bad news is that CVS/Caremark didn't agree to that deal without the promise of a rebate which will further reduce the gross retail to net reported sales difference.quote: the bad news is that CVS/Caremark didn't agree to that deal without the promise of a rebate which will further reduce the gross retail to net reported sales difference. Reply: part of the reason for the price change/increase to unit pricing. (?)
|
|
|
Post by peppy on May 8, 2018 15:34:23 GMT -5
dreamboatcruise explained it pretty well. For reference, the difference between retail sales reported by Symphony and net sales reported by Mannkind has been running about 50%. Also you should be aware of "good news, bad news" announcements such as the agreement for CVS/Caremark to list Afrezza on some of their tier 3/4 formularies. The good news is that more patients will have at least some insurance coverage for their medication and that could help future retail sales, but the bad news is that CVS/Caremark didn't agree to that deal without the promise of a rebate which will further reduce the gross retail to net reported sales difference.quote: the bad news is that CVS/Caremark didn't agree to that deal without the promise of a rebate which will further reduce the gross retail to net reported sales difference. Reply: part of the reason for the price change/increase to unit pricing. (?) Regarding MNKD sales. Just talking here. So Winston Smith showed up here, diagnosed, got afrezza upon request, using a libre says Afrezza is amazing; does not understand why sales aren't better. Golfeverydays son 18 years old diagnosed as a type 1, is 18 years old and the nurse practitioner who is a type one mentioned/suggested afrezza for her patient. Things are changing already and the American Diabetes Association, STAT study presentation is going to be amazing. GROWTH.
|
|
|
Post by peppy on May 8, 2018 15:53:47 GMT -5
I think that peppy is one of those "natural born killers", which is one of the reasons that, even though she's my neighbor - geographically speaking - I've never sought her out for a cup of coffee and a long discussion about chameleons and their instinct to change colors whenever the need arises. It's a protective thing. My instinct tells me that peppy does not need protecting. :-) Liane is going to kill me this is so off topic. Is the health care office located in Saint Louis Park MN called 'The International Diabetes Center ' because they mostly prescribe Novo Nordisk or Sanofi diabetes products? I can not figure it out, it is too difficult for me. Kendall directed it at one time in his career. Nadathing is on it for us. Let's see some Minnesota/afrezza/libre. www.parknicollet.com/for-health-professionals/international-diabetes-center
|
|
|
Post by nylefty on May 8, 2018 16:48:01 GMT -5
baba, I really don't want to know what happens on your couch. That said, any bickering over coverage is interesting but insignificant if sales growth doesn't follow suit. Results are quite different than expectations...and I'm not talking about the couch here. ;-) The CEO has said a few times that lack of coverage of Afrezza isn't the big issue with slow sales. I would like Castagna to explain what is. Seems pretty clear to me. Too many doctors aren't prescribing Afrezza and too many of those who do are failing to properly instruct their patients on how to use it.
|
|
|
Post by peppy on May 9, 2018 14:28:35 GMT -5
|
|
|
Post by awesomo on May 9, 2018 14:39:14 GMT -5
I'm expecting nothing from this call, so we're good to go!
|
|
|
Post by hellodolly on May 9, 2018 15:00:18 GMT -5
I'm expecting nothing from this call, so we're good to go! That is a nice causal approach. If something exciting happens, then you can jump up and down and be surprised. That's better than someone proclaiming, "I knew this all along" but, never said anything. Good luck.
|
|